La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Incannex Healthcare a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Incannex Healthcare..

Incannex Healthcare (NASDAQ:IXHL) Azioni, Catena delle Opzioni

Incannex Healthcare

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Incannex Healthcare Inc

News

Management

Press Releases

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

Power Metallic (TSXV: PNPN | OTCQB: PNPNF) Confirms PGE-Copper Discovery at Lion – High Recovery Potential – More Stocks Inside

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

Health Care

General

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term

Peraso Inc. (NASDAQ: PRSO) Signals Turnaround – Reports Financials August 11, 2025 – More Stocks Inside

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

Investor Alert: NBY, OP, STAI, PNPNF – Stocks Under $1 Complete Watch List Inside

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

AMOD

BTOG

CSE:ELEM

CSE:ESAU

DNUT

ELMGF

ESAUF

GPRO

IXHL

KAVL

PCSA

PNPNF

PRSO

STAI

TSXV:PNPN

AN2 Therapeutics

Aytu BioPharma

CalciMedica

Cingulate

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Curanex Pharmaceuticals Inc - Common Stock

Curanex Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

Hoth Therapeutics

IGC Pharma

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

ProPhase Labs

PolyPid

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

SCYNEXIS

SenesTech

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Comments

Incannex Healthcare

Incannex Healthcare (IXHL) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO